Seoulin Bioscience Co.Ltd
Seoulin Bioscience Co.,Ltd., a bio healthcare company, provides solutions in life sciences and healthcare primarily in South Korea. The company offers solutions for bio research and production; ecoTree, a SLB-120 instrument which produces slightly acidic electrolyzed water for used in food industry, living, and laboratory; plasma-based medical esthetics; miQ for the diagnosis of dementia; and fun… Read more
Seoulin Bioscience Co.Ltd (038070) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.032x
Based on the latest financial reports, Seoulin Bioscience Co.Ltd (038070) has a cash flow conversion efficiency ratio of 0.032x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩2.78 Billion) by net assets (₩86.36 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Seoulin Bioscience Co.Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Seoulin Bioscience Co.Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Seoulin Bioscience Co.Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Seoulin Bioscience Co.Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Hoffmann Green Cement Technologies
PA:ALHGR
|
-0.100x |
|
SRV YHTIOET OYJ
F:B7J1
|
N/A |
|
BF Investment Limited
NSE:BFINVEST
|
0.001x |
|
Chumporn Palm Oil Industry Public Company Limited
BK:CPI
|
-0.054x |
|
K Way Information
TWO:5201
|
0.065x |
|
HFB Financial Corp
PINK:HFBA
|
0.021x |
|
JUNGDAWN Co. Ltd
KQ:208140
|
0.032x |
|
Capita PLC
PINK:CTAGF
|
0.045x |
Annual Cash Flow Conversion Efficiency for Seoulin Bioscience Co.Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of Seoulin Bioscience Co.Ltd from 2013 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩83.89 Billion | ₩-4.61 Billion | -0.055x | -590.65% |
| 2023-12-31 | ₩83.06 Billion | ₩930.57 Million | 0.011x | +121.55% |
| 2022-12-31 | ₩83.79 Billion | ₩-4.36 Billion | -0.052x | -143.64% |
| 2021-12-31 | ₩74.86 Billion | ₩8.92 Billion | 0.119x | +93.73% |
| 2020-12-31 | ₩59.92 Billion | ₩3.68 Billion | 0.061x | -49.85% |
| 2019-12-31 | ₩59.71 Billion | ₩7.32 Billion | 0.123x | +57.79% |
| 2018-12-31 | ₩53.72 Billion | ₩4.17 Billion | 0.078x | +207.51% |
| 2017-12-31 | ₩51.49 Billion | ₩1.30 Billion | 0.025x | -55.42% |
| 2016-12-31 | ₩48.60 Billion | ₩2.76 Billion | 0.057x | -37.62% |
| 2015-12-31 | ₩45.30 Billion | ₩4.12 Billion | 0.091x | +43.12% |
| 2014-12-31 | ₩43.14 Billion | ₩2.74 Billion | 0.063x | -46.57% |
| 2013-12-31 | ₩41.57 Billion | ₩4.94 Billion | 0.119x | -- |